

# DHSC application for summary judgment dismissed

RNS Number : 7004M  
Novacyt S.A.  
01 May 2024

**Novacyt S.A.**

**("Novacyt", the "Company" or the "Group")**

## **DHSC application for summary judgment dismissed**

**Paris, France, and Eastleigh and Manchester, UK - 1 May 2024** - Following the announcement on 19 April 2024, Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, notes the judgment by Mrs Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment.

The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.

## **Contacts**

**Novacyt SA** <https://novacyt.com/investors>

Lyn Rees, Chief Executive Officer **Via Walbrook PR**

Steve Gibson, Chief Financial Officer

---

**SP Angel Corporate Finance LLP (Nominated Adviser and Broker)** +44 (0)20 3470 0470

---

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)

---

**Deutsche Numis (Joint Broker)**

+44 (0)20 7260 1000

---

Freddie Barnfield / Duncan Monteith / Michael Palser

---

**Allegra Finance (French Listing Sponsor)**  
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /  
y.petit@allegrafinance.com

---

**Walbrook PR (Financial PR & IR)**  
Stephanie Cuthbert / Paul McManus /  
Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com  
+44 (0)7796 794 663 / +44 (0)7980 541 893  
+44 (0)7867 984 082 / +44 (0)7407 804 654

---

#### **About Novacyt Group** ([www.novacyt.com](http://www.novacyt.com))

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

|                        |   |
|------------------------|---|
| <b>Clinical</b>        | Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas: <ul style="list-style-type: none"><li>· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests</li><li>· Precision Medicine: DPYD genotyping assay</li><li>· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel</li></ul> |
| <b>Instrumentation</b> | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: <ul style="list-style-type: none"><li>· Ranger® Technology: automated DNA sample preparation and target enrichment technology</li><li>MyGo: real-time quantitative PCR (qPCR) instruments</li></ul>   |

---

**Research Use Only**

Range of services for the research industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
  - Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
- 

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAXLEDDNLEFA